Pritchett Wendy, Kinsley Karen
Memorial Sloan Kettering Cancer Center.
Clin J Oncol Nurs. 2016 Oct 1;20(5):555-6. doi: 10.1188/16.CJON.555-556.
Fosaprepitant dimeglumine (Emend IV®) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. Aprepitant (Emend®) is an oral medication that is administered for three consecutive days, whereas fosaprepitant is a single-dose IV medication that is administered on the day of chemotherapy for 20-30 minutes (depending on the IV access type). Fosaprepitant may be useful, yet it can also present a risk for hypersensitivity reactions and phlebitis. Oncology nurses must be aware of the signs and symptoms of these potential adverse events to properly care for their patients.
磷丙泊酚二钠（Emend IV®）是一种静脉用止吐药，可能对接受高致吐性化疗方案的患者有益。阿瑞匹坦（Emend®）是一种口服药物，需连续服用三天，而磷丙泊酚二钠是一种单剂量静脉用药，在化疗当天给药，持续20 - 30分钟（取决于静脉通路类型）。磷丙泊酚二钠可能有用，但也可能有过敏反应和静脉炎的风险。肿瘤专科护士必须了解这些潜在不良事件的体征和症状，以便妥善护理患者。
